News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Walgreen’s New Medication Management Program May Foreshadow Similar Models for Clinical Laboratory Services

Innovative care management models offer potential opportunities to expand medical laboratory testing services

Reducing hospital readmissions is a major goal and Walgreen Co. (NYSE:WAG) wants to do its part using a new medication management program. The retail pharmacy giant has entered contracts with about a dozen providers to deliver prescriptions to hospitalized patients and manage their medications for the first 30 days after discharge.

Pathologists and clinical laboratory managers know that preventable hospital readmissions cost the U.S. healthcare system approximately $25 billion per year. That figure was provided by a Walgreen’s press release. Among Medicare patients, about 20% are re-hospitalized within 30 days of discharge, the release stated.

“When a patient leaves the hospital with a new medication regimen, it can be overwhelming for both the individual and a caregiver,” observed Kermit R. Crawford, President, Pharmacy, Health and Wellness Division at Walgreens, in the release. (more…)

Medicare and Medicaid Under-Reimbursement Continues to Drive Healthcare Providers Out of the Programs

No clinical pathology laboratories are known to have ceased serving Medicare and Medicaid patients


It’s widely acknowledged by physicians and other providers that Medicaid reimbursement in many states is significantly less than the true cost of providing the service. There are also many types of health procedures where Medicare reimbursement fails to fully reimburse the provider. Thus, it is an important signal when two prominent healthcare organizations announce that—in certain locations and for certain services—they will no longer serve Medicaid or Medicare patients.

Pathologists and clinical laboratory managers will soon see an increasing number of healthcare providers decide to cease serving Medicare and/or Medicare patients. Just in the past 12 months, such nationally respected healthcare organizations as Walgreens and Mayo Clinic have announced that, in certain markets, they will no longer serve new Medicare and/or Medicaid patients. The details of these decisions are revealing.

In the State of Washington, earlier this spring, Walgreens (NYSE:WAG) announced that all 121 of its pharmacies in the state would no longer accept new Medicaid patients. This followed an earlier announcement by the Bartell Drugs chain that its 44-store chain would also no longer serve new Medicaid patients in Washington State.

(more…)

;